Kezar Life Sciences said a partial clinical hold on a trial for its zetomipzomib program to treat autoimmune hepatitis has been lifted by the Food and Drug Administration. The FDA lifted the hold ...

The FDA has lifted one of the two clinical holds placed on Kezar Life Sciences’ zetomipzomib, leading the biotech to speculate on whether to reignite another program for the same drug that remains ...

US FDA lifts clinical hold on PORTOLA phase 2a trial of Kezar Life Sciences for evaluating zetomipzomib to treat autoimmune hepatitis: South San Francisco, California Friday, July ...

The CEO of GH Research, Dr. Velichka Valcheva, pointed out that the response addressed the FDA’s requests with comprehensive ...

Investing.com -- Kezar Life Sciences Inc (NASDAQ: KZR) stock gained 4% after the FDA lifted a partial clinical hold on its completed Phase 2a trial evaluating zetomipzomib in patients with autoimmune ...

Sarepta Therapeutics lays off 493 workers amid FDA probe, stock drop, and concerns over its gene therapy treatment, Elevidys.

Neurizon Therapeutics has announced it has received positive feedback from the US Food and Drug Administration (FDA) on its strategy to lift the clinical hold on its lead drug NUZ-001. The Company ...

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is one of the best oversold NASDAQ stocks to buy now. In a report released on ...

Vyne Therapeutics has given up hopes of resuming a plaque psoriasis trial for its BET inhibitor placed on hold by the FDA, ...

Sarepta Therapeutics announced a layoff of 493 employees, including 80 in Franklin County, amid restructuring efforts and ...

Caribou Biosciences' allogeneic CAR T-cell therapies show promising early efficacy and safety, but require clinical ...

Discover why Takeda Pharmaceutical Company Limited remains a solid Buy. Click to explore TAK and its drug pipeline, growth ...